Tak­ing on gam­ma delta T cells, blue­bird pays $16M for TC Bio­Phar­m's tu­mor in­vad­ing tech plat­form

Gene ther­a­py pi­o­neer blue­bird bio is team­ing up with Scot­land’s TC Bio­Pharm to get its hands on an ex­per­i­men­tal pro­gram in­volv­ing an emerg­ing im­munother­a­py plat­form: CAR-en­gi­neered gam­ma delta T cells.

As part of the deal, blue­bird $BLUE is pay­ing TC Bio­Pharm (TCB) a $16 mil­lion up­front pay­ment, with undis­closed mile­stones and roy­al­ties down the road. TCB will be re­spon­si­ble for de­vel­op­ing tar­gets through Phase I/II, while blue­bird has the ex­clu­sive op­tion to take on fur­ther clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion world­wide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER